Skip to main content
Clinical Trials/IRCT20161010030246N6
IRCT20161010030246N6Not yet recruitingPhase 3

Evaluating the effectiveness of silymarin in preventing vancomycin-induced nephrotoxicity in hospitalized patients

Shiraz University of Medical Sciences0 sites80 target enrollmentStarted: TBDLast updated:
Conditions

Trial Snapshot

Phase
Phase 3
Status
Not yet recruiting
Enrollment
80

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 years to no limit (—)
Sex
All

Inclusion Criteria

  • Hemodynamic stability (mean arterial blood pressure above 70 mmHg and/or systolic blood pressure above 90 mmHg.
  • Willingness to participate in the study
  • Receiving vancomycin intravenously for at least 1 week with the maintenance dosage regimen of 30-45 mg/kg/day or 1-2 g twice a day. Notably, the vancomycin regimen is the same in both hospitals.

Exclusion Criteria

  • Confirmed history of acute kidney injury
  • Confirmed history of chronic kidney disease
  • Taking vancomycin within the last 14 days
  • Taking silymarin orally at least during the past day
  • Confirmed history of hypersensitivity reactions following oral consumption of silymarin
  • Simultaneous use of agents with antioxidant activity such as vitamin C, vitamin E, vitamin A, melatonin
  • Receiving drugs with high nephrotoxicity potential such as aminoglycosides, amphotericin b, colistin
  • Oral intolerance to drugs

Investigators

Similar Trials